Abstract
Dupilumab demonstrated improvements in patient-reported daily symptom severity scores in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This post hoc analysis assessed the proportion of patients with symptom-free days (SFD) in the Phase 3 SINUS-24/SINUS-52 studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
